Craft
Seikagaku

Seikagaku

Revenue

¥34.9 B

FY, 2022

Market Capitalization

¥53.9 B

2022-11-25

Seikagaku Summary

Company summary

Overview
Seikagaku is a company that manufactures and sells pharmaceuticals and medical devices related to glycoconjugates. It operates within two segments: a Pharmaceutical and a LAL business. The Pharmaceutical segment is engaged in the manufacture of pharmaceuticals and medical devices with glycoconjugates, specifically, glycosaminoglycans (GAG) such as hyaluronic acid as well as enzymes that act on GAG. The LAL segment is dedicated to the manufacture and commercializing of endotoxin-detecting reagents, made from limulus amebocyte lysate, that are used to test for endotoxins in pharmaceuticals and medical devices.
Type
Public
Status
Active
Founded
1947
Website
https://www.seikagaku.co.jp/ja/index.html
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Seikagaku Financials

Summary financials

Revenue (Q1, 2023)
¥8.3B
Gross profit (Q1, 2023)
¥5.0B
Net income (Q1, 2023)
¥1.5B
Cash (Q1, 2023)
¥21.0B
EBIT (Q1, 2023)
¥1.1B
Enterprise value
$33.4B

Footer menu